Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
NCT07340541
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospective data collection, including archival tumor tissue, medical record abstraction, and prospective tumor and blood sampling prior to initiation of protocol directed treatment. Based on biomarker subtype, participants will receive standard of care therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- Hormone Receptor Negative Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale Cancer Center Clinical Trials Office · New Haven, CT
Maryland · 1
- Johns Hopkins University/Sidney Kimmel Cancer Center · Baltimore, MD
North Carolina · 1
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill · Chapel Hill, NC
Pennsylvania · 1
- University of Pennsylvania/Abramson Cancer Center · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.